109 related articles for article (PubMed ID: 16810502)
1. Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma.
Fukui K; Tamura S; Wada A; Kamada Y; Sawai Y; Imanaka K; Kudara T; Shimomura I; Hayashi N
J Cancer Res Clin Oncol; 2006 Oct; 132(10):627-33. PubMed ID: 16810502
[TBL] [Abstract][Full Text] [Related]
2. Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy.
Sun FK; Sun Q; Fan YC; Gao S; Zhao J; Li F; Jia YB; Liu C; Wang LY; Li XY; Ji XF; Wang K
J Gastroenterol Hepatol; 2016 Feb; 31(2):484-92. PubMed ID: 26313014
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients.
Ng L; Kwan V; Chow A; Yau TC; Poon RT; Pang R; Law WL
BMC Cancer; 2019 Jul; 19(1):713. PubMed ID: 31324164
[TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.
Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T
Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283
[TBL] [Abstract][Full Text] [Related]
5. The role of MTA1 gene expression in human hepatocellular carcinoma.
Hamatsu T; Rikimaru T; Yamashita Y; Aishima S; Tanaka S; Shirabe K; Shimada M; Toh Y; Sugimachi K
Oncol Rep; 2003; 10(3):599-604. PubMed ID: 12684630
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma.
Li XR; Ji F; Ouyang J; Wu W; Qian LY; Yang KY
Eur J Surg Oncol; 2006 Dec; 32(10):1130-4. PubMed ID: 16806792
[TBL] [Abstract][Full Text] [Related]
7. MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.
Liu W; Wang N; Lu M; Du XJ; Xing BC
Mol Med Rep; 2016 Aug; 14(2):1617-23. PubMed ID: 27315121
[TBL] [Abstract][Full Text] [Related]
8. Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.
Hu T; Guo H; Wang W; Yu S; Han L; Jiang L; Ma J; Yang C; Guo Q; Nan K
Oncol Rep; 2013 Oct; 30(4):1707-14. PubMed ID: 23842948
[TBL] [Abstract][Full Text] [Related]
9. Involvement of RhoA in progression of human hepatocellular carcinoma.
Wang D; Dou K; Xiang H; Song Z; Zhao Q; Chen Y; Li Y
J Gastroenterol Hepatol; 2007 Nov; 22(11):1916-20. PubMed ID: 17914970
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
[TBL] [Abstract][Full Text] [Related]
11. Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma.
Xiaorong L; Wei W; Liyuan Q; Kaiyan Y
BMC Cancer; 2008 Jul; 8():205. PubMed ID: 18651974
[TBL] [Abstract][Full Text] [Related]
12. GEF-H1 over-expression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling.
Cheng IK; Tsang BC; Lai KP; Ching AK; Chan AW; To KF; Lai PB; Wong N
J Pathol; 2012 Dec; 228(4):575-85. PubMed ID: 22847784
[TBL] [Abstract][Full Text] [Related]
13. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
14. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection.
Truant S; Boleslawski E; Duhamel A; Bouras AF; Louvet A; Febvay C; Leteurtre E; Huet G; Zerbib P; Dharancy S; Hebbar M; Pruvot FR
Eur J Surg Oncol; 2012 Dec; 38(12):1189-96. PubMed ID: 22863304
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic significance of urinary trypsin inhibitor in patients with hepatocellular carcinoma after hepatectomy.
Kikuchi I; Uchinami H; Nanjo H; Hashimoto M; Nakajima A; Kume M; Mencin A; Yamamoto Y
Ann Surg Oncol; 2009 Oct; 16(10):2805-17. PubMed ID: 19636634
[TBL] [Abstract][Full Text] [Related]
16. Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.
Zheng H; Yang Y; Wang MC; Yuan SX; Tian T; Han J; Ni JS; Wang J; Xing H; Zhou WP
Surg Oncol; 2016 Sep; 25(3):171-7. PubMed ID: 27566019
[TBL] [Abstract][Full Text] [Related]
17. p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection.
Wang XM; Yang LY; Guo L; Fan C; Wu F
Cancer; 2009 Oct; 115(19):4554-63. PubMed ID: 19551892
[TBL] [Abstract][Full Text] [Related]
18. RPL36 as a prognostic marker in hepatocellular carcinoma.
Song MJ; Jung CK; Park CH; Hur W; Choi JE; Bae SH; Choi JY; Choi SW; Han NI; Yoon SK
Pathol Int; 2011 Nov; 61(11):638-44. PubMed ID: 22029674
[TBL] [Abstract][Full Text] [Related]
19. Microfilament regulatory protein MENA increases activity of RhoA and promotes metastasis of hepatocellular carcinoma.
Lin L; Yang XM; Li J; Zhang YL; Qin W; Zhang ZG
Exp Cell Res; 2014 Sep; 327(1):113-22. PubMed ID: 24859350
[TBL] [Abstract][Full Text] [Related]
20. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function.
Ahn SG; Jeon TJ; Lee SD; Kim SH; Cho HJ; Yun M; Park YN; Lee JD; Park SJ; Kim KS
Eur J Surg Oncol; 2013 Sep; 39(9):964-73. PubMed ID: 23859893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
